Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone

• Published in: Annals of oncology Vol. 18; no. 5; pp. 903 - 908
• Main Authors: Novello, S, Bruzzi, P, Barone, C, Buosi, R, Masotti, A, Michetti, G, Fioretti, M, Barbera, S, Spatafora, M, Garetto, L, Mazzanti, P, Dongiovanni, V, Selvaggi, G, Crinò, L, Scagliotti, GV
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.05.2007; Oxford Publishing Limited (England)
• Subjects: Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; chemotherapy; cisplatin; Cisplatin - administration & dosage; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Drug Administration Schedule; Female; Follow-Up Studies; gemcitabine; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Medical sciences; metastatic disease; Middle Aged; Neoplasm Staging; non-small-cell lung cancer; Pharmacology. Drug treatments; Pneumology; Survival Analysis; Time Factors; Treatment Outcome; Tumors of the respiratory system and mediastinum; gemcitabine; cisplatin; metastatic disease; chemotherapy; non-small-cell lung cancer; Antineoplastic agent; Phase III trial; Human; Lung disease; Gemcitabine; Respiratory disease; Lung cancer; Malignant tumor; Metastasis; non-small cell lung carcinoma; Cisplatin; Alkylating agent; Chemotherapy; Randomization; Treatment; Antimetabolic; Bronchus disease; Pyrimidine derivatives; Advanced stage; Fluorine Organic compounds; Pyrimidine nucleoside; Platinum II Complexes
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdm061

Background: This randomised phase III study investigated if in responsive and stable disease (SD) stage IV patients after two courses of cisplatin and gemcitabine, single-agent gemcitabine (experimental arm) was not inferior in terms of overall survival (OS) to cisplatin–gemcitabine (standard arm). Patients and methods: Noninferiority was defined as an increase in the hazard of death (HR) ≤1.33 in the experimental arm. From January 2001 to February 2004, 340 patients were registered and 250 were randomised. Cisplatin was administered on day 1 at 75 mg/m2 and Gemcitabine on days 1 and 8 at 1250 mg/m2 every 3 weeks. Results: Response rate after two courses was 29%. The 1-year progression-free survival was 13% in both arms. One-year survival was 52% in the standard and 42% in the experimental arm for an HR of 1.21 [90% confidence interval (CI) 0.97–1.51]. Postprogression survival was in favour of the standard arm (HR 1.30, 95% CI 0.99–1.70, P = 0.051). Grades 3–4 toxicity favoured in the experimental arm. Conclusion: In responsive and SD patients with stage IV non-small-cell lung cancer it was not possible to demonstrate that three courses of gemcitabine alone are not inferior, in terms of OS, to the standard approach of three courses of cisplatin–gemcitabine.